Association of Daily Growth Hormone Injection Adherence and Height Among Children With Growth Hormone Deficiency

Jane Loftus, Bradley S. Miller, Craig S. Parzynski, Jose Alvir, Yong Chen, Priti Jhingran, Anu Gupta, Mitch DeKoven, Victoria Divino, Jenny Tse, Jing He, Michael Wajnrajch

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

OBJECTIVE: Recombinant human growth hormone (somatropin) is recommended for children with growth hormone deficiency (GHD) to normalize adult height. Prior research has indicated an association between adherence to somatropin and height velocity. Further research is needed using real-world data to quantify this relationship; hence the objective of this study was to investigate the association between adherence to somatropin and change in height among children with GHD.

METHODS: This retrospective cohort study included patients in the IQVIA PharMetrics Plus and Ambulatory Electronic Medical Records databases aged 3 to 15 years, with ≥1 GHD diagnosis code claim and newly initiated on somatropin between January 1, 2007 and November 30, 2019. Adherence was measured over the follow-up using the medication possession ratio (MPR); patients were classified as adherent (MPR ≥ 0.8) or nonadherent (MPR < 0.8).

RESULTS: Among 201 patients initiated on somatropin, 74.6% were male, mean age was 11.4 years, and the mean follow-up was 343.3 days. Approximately 76.6% of patients were adherent to somatropin over the follow-up period. Adjusted growth trajectories were similar between adherent and nonadherent patients pre-treatment initiation (P = .15). Growth trajectories post-initiation were significantly different (P = .001). On average, adherent patients gained an additional 1.8 cm over 1 year compared with nonadherent patients, adjusted for covariates.

CONCLUSION: Greater adherence to somatropin therapy is associated with improved height velocity. As suboptimal adherence to daily somatropin therapy is an issue for children with GHD, novel strategies to improve adherence may improve growth outcomes.

Original languageEnglish (US)
Pages (from-to)565-571
Number of pages7
JournalEndocrine Practice
Volume28
Issue number6
DOIs
StatePublished - Jun 2022

Bibliographical note

Funding Information:
This study was sponsored by Pfizer .

Funding Information:
This study was sponsored by Pfizer. J.L. J.A. Y.C. A.G. and M.W. are employees of Pfizer and report ownership of Pfizer stock. C.S.P. and P.J. are employees of Genesis Research who were paid consultants to Pfizer in connection with this research and development of this manuscript. M.D. V.D. J.T. and J.H. are employees of IQVIA and were paid consultants to Pfizer in connection with this research and development of this manuscript. B.S.M. is a consultant for Abbvie, Ascendis Pharma, BioMarin, EMD Serono, Novo Nordisk, Orchard Therapeutics, Pfizer, Sandoz, Tolmar and Vertice Pharma and has received research support from Alexion, Abbvie, Amgen, Lumos Pharma, Novo Nordisk, Opko Health, and Pfizer.

Publisher Copyright:
© 2022 AACE

Keywords

  • adherence
  • growth
  • height
  • pediatric growth hormone deficiency
  • somatropin

Fingerprint

Dive into the research topics of 'Association of Daily Growth Hormone Injection Adherence and Height Among Children With Growth Hormone Deficiency'. Together they form a unique fingerprint.

Cite this